Janssen to Acquire Investigational Bermekimab from XBiotech
Janssen to Acquire Investigational Bermekimab from XBiotech 3Clinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa HORSHAM, Pa., Dec. 7, 2019 /PRNewswire/ — Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab …
News story posted on 2019-12-07T07:53:00.0000000Z